We are live on ! Find out more
DRNA

Dicerna Pharmaceuticals
DRNA

Delisted

DRNA was delisted on the 27th of December, 2021.

41 hedge funds and large institutions have $274M invested in Dicerna Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 7

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

7% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 14

1.16% less ownership

Funds ownership: 69.53% → 68.37% (-1.2%)

2% less funds holding

Funds holding: 42 → 41 (-1)

50% less capital inflows, than outflows

Capital inflows: $10.4M | Capital outflows: $21M

Holders
41
Holders Change
-1
Holders Change %
-2.38%
% of All Funds
1.17%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
13
Increased
13
Reduced
7
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

DRNA Hedge Fund Activity: Q2 2014 in Review

41 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals (DRNA) for Q2 2014, worth a combined $274M — down 21% from $349M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of DRNA and 13 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 13 added.

The largest buyer was Sabby Management, adding an estimated $1.84M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $4.88M sold.

  • 41 institutional investors held Dicerna Pharmaceuticals (DRNA) as of Q2 2014, down from 42 in Q1 2014.
  • Funds reported $274M of Dicerna Pharmaceuticals stock for Q2 2014, down 21% quarter-over-quarter.
  • 13 funds opened new Dicerna Pharmaceuticals positions in Q2 2014 and 14 closed out, a net change of -1 holder.
  • The largest Dicerna Pharmaceuticals buyer in Q2 2014 was Sabby Management, an estimated $1.84M added.
  • The largest Dicerna Pharmaceuticals seller in Q2 2014 was T. Rowe Price Associates, an estimated $4.88M sold.

Based on aggregated 13F filings for Q2 2014.